<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00418730</url>
  </required_header>
  <id_info>
    <org_study_id>NEOSH101-CLIN-AGA003</org_study_id>
    <nct_id>NCT00418730</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss</brief_title>
  <official_title>A Phase 2 Multicenter, Randomized, Placebo- and Comparator-Controlled, Double-Blind Parallel Group Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neosil, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neosil, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure the hair growth response to topical NEOSH101 when
      applied twice daily to the balding scalp for 16 weeks. One hundred eighty men with
      Norwood/Hamilton grades III-IV with thinning in the top and center of the scalp will
      participate. Three equally sized treatment groups (60 men each) will receive either topical
      NEOSH101 2.0%, minoxidil 5%, or placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hair density, hair growth rate, hair diameter as measured using the TrichoScan method</measure>
    <time_frame>Through Study Day 197</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment score of dermal tolerability</measure>
    <time_frame>Through Study Day 197</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's global assessment score</measure>
    <time_frame>Through Study Day 197</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Androgenetic Alopecia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tetrapeptide aldehyde proteasome inhibitor (NEOSH101)</intervention_name>
    <description>Study preparation (experimental, active comparator, placebo comparator) will be applied twice daily to the scalp for 112 days</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasian men, in general good health, aged 18-49 years

          -  Norwood/Hamilton grades III-IV, with thinning hair in the vertex area

        Exclusion Criteria:

          -  concomitant dermatologic or medical condition(s) which may interfere with the
             investigator's ability to evaluate the subject's response to the study drug

          -  treatment with a systemic or locally acting medication which may interfere with the
             study objectives, such as minoxidil treatment in the 6 months prior to study start,
             finasteride treatment in the 12 months prior to study start, or treatment with other
             investigational hair growth products in the 6 months prior to study start
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Gassmueller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bioskin GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>bioskin Institute for Dermatological Research and Development GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2007</study_first_submitted>
  <study_first_submitted_qc>January 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2007</study_first_posted>
  <last_update_submitted>May 16, 2008</last_update_submitted>
  <last_update_submitted_qc>May 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2008</last_update_posted>
  <responsible_party>
    <name_title>Andria Langenberg, MD, Vice President, Clinical Development</name_title>
    <organization>Neosil, Inc.</organization>
  </responsible_party>
  <keyword>androgenetic alopecia</keyword>
  <keyword>male pattern hair loss</keyword>
  <keyword>male pattern baldness</keyword>
  <keyword>androgenetic alopecia or male pattern hair loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proteasome Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

